Tri-luma Patent Expiration

Tri-luma is a drug owned by Galderma Laboratories Lp. It is protected by 4 US drug patents filed from 2013 to 2014. Out of these, 2 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 22, 2026. Details of Tri-luma's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7915243 Topical skin care composition
Mar, 2026

(1 year, 5 months from now)

Active
US7939516 Topical skin care composition
May, 2025

(6 months from now)

Active
US8653053 Topical skin care composition
Oct, 2022

(1 year, 11 months ago)

Expired
US8247395 Topical skin care composition
Oct, 2022

(1 year, 11 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tri-luma's patents.

Given below is the list of recent legal activities going on the following patents of Tri-luma.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 08 Apr, 2024 US8247395
Payment of Maintenance Fee, 12th Year, Large Entity 07 Nov, 2022 US7939516
Payment of Maintenance Fee, 12th Year, Large Entity 21 Sep, 2022 US7915243
Payment of Maintenance Fee, 8th Year, Large Entity 06 Feb, 2020 US8247395
Payment of Maintenance Fee, 8th Year, Large Entity 25 Oct, 2018 US7939516
Payment of Maintenance Fee, 8th Year, Large Entity 13 Sep, 2018 US7915243
Patent Issue Date Used in PTA Calculation 21 Aug, 2012 US8247395
Recordation of Patent Grant Mailed 21 Aug, 2012 US8247395
Issue Notification Mailed 01 Aug, 2012 US8247395
Dispatch to FDC 23 Jul, 2012 US8247395

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Tri-luma is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tri-luma's family patents as well as insights into ongoing legal events on those patents.

Tri-luma's Family Patents

Tri-luma has patent protection in a total of 18 countries. It's US patent count contributes only to 32.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Tri-luma.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Tri-luma's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 22, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Tri-luma Generics:

There are no approved generic versions for Tri-luma as of now.





About Tri-luma

Tri-Luma is a drug owned by Galderma Laboratories Lp. Tri-Luma uses Fluocinolone Acetonide; Hydroquinone; Tretinoin as an active ingredient. Tri-Luma was launched by Galderma Labs Lp in 2002.

Approval Date:

Tri-luma was approved by FDA for market use on 18 January, 2002.

Active Ingredient:

Tri-luma uses Fluocinolone Acetonide; Hydroquinone; Tretinoin as the active ingredient. Check out other Drugs and Companies using Fluocinolone Acetonide; Hydroquinone; Tretinoin ingredient

Dosage:

Tri-luma is available in cream form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.01%;4%;0.05% CREAM Prescription TOPICAL